The results from the trial demonstrated that the treatment reduced allergic symptoms in patients’ eyes by up to 30% more than placebo.
The trial which involved around 50 patients with hay fever, was conducted in Quebec, Canada.
In the trial, the patients received four doses from one of five different treatment regimes over a 12-week period.
Circassia CEO Steve Harris said their clinical data give them the confidence to proceed with the final phase II testing of their hay fever treatment.